Drug intelligence / Profile preview

Man3-siRNA

Development stage
Unknown
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Subcutaneous, Intratumoral
01

Overview

Man3-siRNA is a synthetic small interfering RNA (siRNA) conjugated with a trimannose (Man3) ligand, designed for targeted gene silencing via the RNA interference pathway. The Man3 ligand is intended to direct the siRNA specifically to cells expressing mannose receptors (for example, antigen-presenting cells or macrophages), enhancing cellular uptake through receptor-mediated endocytosis. Once internalized, the siRNA duplex is incorporated into the RNA-induced silencing complex (RISC), which then uses the antisense strand to bind complementary messenger RNA (mRNA), facilitating its cleavage and degradation. This prevents protein translation and results in targeted gene knockdown. Man3-siRNA is a research or preclinical agent leveraging synthetic siRNA for selective, sequence-dependent inhibition of gene expression at the mRNA level[1][2][3][4][5][6][7].

02

Targets

SPP1 (Osteopontin)

Beyond the preview

Go deeper on Man3-siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Man3-siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call